PRINCETON, N.J., April 14 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY - News) today announced new results of the BARACLUDE® (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment (n=663). In the three nucleoside- naive studies analyzed, two patients, or less than one percent, experienced virologic breakthrough due to BARACLUDE resistance through the third year, and no additional patients developed resistance in the fourth year. In lamivudine- refractory patients, virologic breakthrough due to BARACLUDE resistance occurred in 15 percent (n=8/53) of patients during year four. The study results were presented today at the 42nd Annual Meeting of the European Association for the Study of Liver Diseases (EASL) in Barcelona, Spain.
